Marc Cantillon is a Psychiatry physician. OpenAlex indexes 92 publications with 2,726 citations (h-index 26); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
134 Walnut St
Livingston, NJ 070392513
Telephone
973-462-0496Registry record last updated 19 Jun 2008.
Clinical trials
- Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
Sponsor: Kyowa Kirin Co., Ltd.
- The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Sponsor: Kyowa Kirin Co., Ltd.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202536 payments$24,349openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202539 payments
- Axsome Therapeutics, Inc.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.9%Benzodiazepine27.2%Alprazolam47%Clonazepam37%Lorazepam8%Diazepam5%Valium3%Part D<11 patientsAtypical Antipsychotic21.2%Vraylar38%Quetiapine Fumarate36%Olanzapine9%Aripiprazole7%Ziprasidone Hcl6%Caplyta4%Part D<11 patients+ 15 more classes in this area
Cardiovascular
2.1%Central alpha-2 Adrenergic Agonist1%Clonidine Hcl100%Part D<11 patientsalpha-Adrenergic Blocker1%Prazosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
npj Parkinson s Disease
2024 - Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease
The Journal of Prevention of Alzheimer s Disease
2024 - Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials
American Journal of Geriatric Psychiatry
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”